Click on the YouTube ICON to watch the video.
Though this recording has been made by One Ashford Hospital, I perform the procedure at Chaucer Hospital, Canterbury; Spire Tunbridge Wells, and the Mcindoe Centre, East Grinstead.
|
Breast reduction surgery brings about significant benefits: backache, neckache , bra-strap shoulder indentations and intertrigo (redness under the breast in the creases) are vastly improved after surgery. It also becomes easier to find clothes that fit. In this You-Tube video, I have outlined the benefits, recovery and complications from surgery.
Click on the YouTube ICON to watch the video. Though this recording has been made by One Ashford Hospital, I perform the procedure at Chaucer Hospital, Canterbury; Spire Tunbridge Wells, and the Mcindoe Centre, East Grinstead.
0 Comments
BIA-ALCL
A rare type of immune system cell cancer called Anaplastic Large Cell Lymphoma (ALCL) is linked to silicone breast implants. ALCL is a lymphoma and not cancer of the breast tissue. In women with breast implants, ALCL was found adjacent to the implant itself and contained within the fibrous capsule. The condition presents usually with a late onset seroma (fluid collection around the implant) some years after surgery, and is usually treated with capsulectomy alone, though some cases require chemotherapy. The first case was reported in 1997, yet it is important to note that breast implants have been used since 1962, with current numbers showing there are over 10 million women in the world with breast implants. The current risk of developing ALCL associated with breast implants is placed at 1:24,000. As of September 30, 2017, the FDA in USA had received a total of 414 medical device reports (MDRs) of BIA-ALCL, including the death of nine patients. 272 of the 414 reports included information on the surface information of the implant at the time of the report, including 242 with textured surfaces and 30 with smooth surfaces. 413 of the 414 reports included information on implant fill types. Of these, 234 reported implants filled with silicone gel and 179 reported implants filled with saline. https://www.fda.gov/medicaldevices/productsandmedicalprocedures/implantsandprosthetics/breastimplants/ucm239995.htm As of September 2018, MHRA in the UK has received 57 reports of ALCL in patients with breast implants, 45 of which meet the WHO diagnostic criteria for BIA-ALCL. In cases of ALCL in women with breast implants reported to MHRA there have been 3 deaths. Only 1 of these is confirmed to meet the diagnostic criteria for BIA-ALCL. The other two deaths did not meet the diagnostic criteria. https://www.gov.uk/guidance/breast-implants-and-anaplastic-large-cell-lymphoma-alcl There is increasingly accepted hypothesis that bacterial contamination introduced at the time of implant surgery may over time lead to a biofilm that triggers an inflammatory and immune response which in conjunction with a patient’s genetic pre-disposition may lead to BIA-ALCL. The creation of a biofilm can be reduced with the use of the 14-point plan. Texturing may contribute to increasing an inflammatory response by increasing the surface area. Breast implant related Anaplastic Large Cell Lymphoma (BI-ALCL) remains a rare condition that has been identified in 650-700 patients worldwide. It appears that there are at least 57 cases identified in the UK. All of the information to date suggests that women with breast implants have a very low but increased risk of developing ALCL compared to women who do not have breast implants. Breast Implant Illness (BII) Breast Implant Illness is a condition that consists of a very broad range of non-specific symptoms such as hair loss, brain fog, general fatigue, fibromyalgia and other associated conditions such as ME, irritable bowel syndrome, various skin conditions and autoimmune conditions such as lupus, rheumatoid, SLE and Raynaud’s. Many of these patients have tried a range of strategies to overcome their ailments, including nutritional advice, changes in diet and a variety of lifestyle changes. Most of them have reached the conclusion that their breast implants are responsible for their malaise and requesting explantation. Though BII has been recognized as a condition that affects some patients with breast implants, currently there is lack of good data and no causal association has been demonstrated in literature so far. The variety of generalised symptoms reported have made it difficult to ascertain the ‘true’ features of the illness and hence an objective diagnosis can be difficult. It is believed that a in some patients, a psychological pre-disposition may lead to development of symptoms. Explantation (removal of implants) appears to only work for 50% patients. Across most of the world including Europe and Australia, the preference is for the use of textured implants in 90% patients, with only 10% smooth being used. The current breakdown of implant usage in the USA is 87% smooth and 13% textured. This discrepancy is due to the moratorium imposed by the FDA in USA in 1992, which led to US surgeons almost exclusively using smooth saline and of late, silicone smooth implants; whereas the rest of the world progressively continued to use textured implants.
Capsular contracture continues to be the leading cause of breast implant re-operations. The key benefit of using textured implants is reduced capsular contracture. As textured implants provide frictional resistance to movement, they also help to stabilise the implant pocket and reduce skin stretch and ‘bottoming out’ in the lower part of the breast over time. Smooth implants, on the other hand, can feel softer, are more easily placed with smaller incisions, however, will have greater movement with some drift to the sides of the breast (lateral slip). They tend to settle in the lower part of the breast, stretching the lower breast skin envelope. Though textured implants have been pre-dominantly been used in the UK and Europe, the concern for the rare occurrence of BIA-ALCL (Breast Implant Associated ALCL) has started to influence the discussion regarding the use of textured vs smooth implants. You should discuss with your surgeon what is best for your body shape, chest wall shape and breast skin envelope. *Longterm safety of textured and smooth breast implants Calobrace et al. Aesthetic Surgery Journal 2018, Vol 38(1) 38-48. A rare type of immune system cell cancer called Anaplastic Large Cell Lymphoma (ALCL) occurs in association with breast implants. ALCL is a lymphoma and not cancer of the breast tissue. In women with breast implants, ALCL has been found adjacent to the implant itself and contained within the fibrous capsule. The condition usually presents at an average of 7-8 years following breast implant surgery with a late onset seroma (fluid collection around the implant), and is treated with capsulectomy alone, though some cases require chemotherapy. The first case was reported in 1997, yet it is important to note that breast implants have been used since 1962, with current numbers showing there are over 10 million women in the world with breast implants. As of February 1, 2017, the FDA in USA received a total of 359 medical device reports (MDRs) of BIA-ALCL, including nine deaths. Out of 231 reports that included information on the implant surface, 203 were reported to be textured implants and 28 reported to be smooth implants. 312 of the 359 reports included information on implant fill types. Of these, 186 reported implants were filled with silicone gel and 126 reported implants filled with saline. In the UK, at least 23 cases have been identified .
Though we do not know what causes BIA-ALCL, there is increasing evidence to support an infective trigger. The time frame for its development fits with a chronic bio-film infection. In addition to the implant surface acting as a passive conduit for bacteria, it is believed that patients with genetic susceptibility and with an abnormal immune response, over time may contribute to the eventual development of BIA-ALCL. The 14 point plan (www.saferbreastimplants.org/about/the-14-point-plan/) has strategies that can be incorporated into surgical practice to prevent implant contamination and may be a useful tool in reducing the risk of BIA-ALCL. To summarise, Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) remains a rare condition that has been identified in 360 patients worldwide. All of the information to date suggests that women with breast implants have a very low but increased risk of developing ALCL compared to women who do not have breast implants. Most cases of breast implant-associated ALCL are treated by removal of the implant and the capsule surrounding the implant, however, some cases may require chemotherapy. Evening primrose oil (EPO) is taken by many women for breast pain. Though it may help with premenstrual breast discomfort, it is one of a long list of natural supplements that must be stopped atleast 2 - 4 weeks prior to surgery.
EPO increases the risk of bleeding during and after your surgery. The gamma-linolenic acid in evening primrose oil can slow blood clotting, so it should not be taken along with medications intended for the same purpose, as this can cause a bleeding and bruising risk. Often after surgery, you will be given an injection to prevent Deep Vein Thrombosis and Pulmonary Embolism (clots in legs and lungs), along with other measures such as TED stockings and Flotron boots. EPO can interact with blood thinning medication. EPO has also been known to cause seizures under general anaesthetic, even though you may not normally have fits. Other natural supplements that have been implicated in an increased risk of bleeding during surgery are garlic, ginger, ginkgo, ginseng, danshen, omega-3 fatty acids, St John wort…… Always tell your doctor about supplements you are taking if you are considering surgery. Just because supplements may be natural, it does not mean that they are safe for surgery. The Breast Cosmetic Implant Registry (BCIR) was launched in the UK in Oct 2016 and is managed by NHS Digital http://www.hscic.gov.uk/clinicalauditplatform. It is track and trace system- in the event of another failure such as PIP implants, patients can be traced and actively managed. It follows the example set by similar breast implants registries in Australia and Netherlands. The data-set has been shared by the Australians and the Dutch via 'icobra' (International Collaboration of Breast Registry Activities) and is embedded in the UK BIR.
However, unlike the other registries which favour mandatory participation, in the UK, a patient has to give consent for her data to be entered into the registry. All patients are actively encouraged to participate in the registry.
As a side effect of my testicular cancer in my thirties, I developed male breasts (gynaecomastia). The right breast was larger and more solid.
Wearing tighter fitting shirts was uncomfortable, and shirts started to gap at the buttons. I come from the southern hemisphere and stripping off around the pool became embarrassing, something I used to take for granted. Most people naturally think that you have man-boobs due to excessive weight, though I am of fairly slim build. However hard ones tries, you cannot shift the fat from the breasts. At the time of my testicular cancer treatment, the surgeon said if I ever wanted to reduce the man-boobs, something could be done. To be honest, I was just glad to be in remission and said ‘maybe later’. When I decided to sort it out, I consulted with several surgeons, as I wanted to understand how the procedure would be done. Miss Hazari was very well-informed. She covered all the basics before surgery to ensure the risks were managed, and explained the options as well as which procedure would give the best outcome. The surgery was different on both sides due to the mass on the right. So liposuction alone was required to the left (as I did not have a fibrous disc behind the nipple). The right breast required skin reduction in addition to liposuction. The right side therefore had an incision around the nipple as well as short horizontal incisions away from the nipple to reduce the excessive skin. Immediately after surgery the results were already apparent. The left breast was greatly reduced and looked completely natural with the exception of the liposuction entry points. These have faded and the tissue behind evened out, so now the scars look like small moles, which blend in amazingly. The right side is more symmetrical to the left with the nipple reduced in size to match. I apply Bio-oil and the scaring is fading nicely. Looking back at how I used to be concerned about my chest appearance and would walk to and from the pool on holiday with a T-shirt or a towel over my right shoulder, I wish I had the procedure many years earlier. The appearance is already so normal, and things can only get better over the next year as the scaring continues to fade. A great result all round! Enlarged male breasts, Gynaecomastia is a common condition causing significant embarrassment. Although it can be associated with hormonal imbalances and testicular tumours (age group 25-45 years), the majority arise in adolescent and middle-aged males in the absence of underlying pathology. Most teenage boys will experience some degree of transient gynaecomastia, which usually subsides in less than two years.
Surgical options very much depend on the degree of excess breast tissue and whether there is excess skin associated with it. It has been graded by Simon as: Grade 1 small, but visible breast tissue with no redundant skin Grade 2a moderate breast development with no skin redundancy Grade 2b moderate breast development with redundant skin Grade 3 marked breast tissue with significant excess skin Treatment: Lower-grade gynaecomastia can be managed with simple excision and/or liposuction of the abnormal tissue (Grade 1–2a). Often, a fibrous disc is present beneath the nipple and this cannot be removed by liposuction alone and will require excision. Higher-grade gynaecomastia, especially that which appears as a female breast will usually require skin excision and, consequently, involves more extensive scarring,making a good aesthetic outcome difficult. The attached photos are before and after combination of liposuction and open excision with a visible scar around the lower nipple, and additional scarring to remove excess skin on the right. One of the two reasons why breast implants need replacing is capsular contracture, the other is rupture or leaks. The implants that I currently use are high cohesive gel by Allergan and Mentor, both are FDA approved. Rupture rates in these implants are low, infact both manufacturers provide a life-time warranty for rupture. Capsular contracture, though, continues to be a problem.
Polyurethane coated implants, supplied by Polytech in the UK may be a solution. These implants have been used in South America for the last 35 years, and were used for a short period of time in the US, but were withdrawn from USA, alongwith all silicone implants in the 1990s during the years of ‘silicone controversy’. The other finding has been the presence of 2,4TDA (toluenediamine) in the urine of women with these implants. But this has finally been resolved too, as TDA has been found in urine of women with no breast implants. Polyurethane is also used in other prosthetics such as heart valves and pacemakers, so safety is no longer an issue. The polyurethane coating does two things:
|
Archives
February 2020
Categories
All
|
Private 01342 330 396
[email protected] ------------------------------------------- NHS 01342 410210 / 01342 414465 [email protected] |